Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

Study of VX-770 and Rifampin in Healthy Male Subjects

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-770
Drug: Rifampin

First Posted Date: 2009-11-23

Last Posted Date: 2010-05-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT01018368

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Phase 2

Completed

Conditions: Hepatitis C
HIV Infections

Interventions: Drug: telaprevir or matching placebo
Biological: peginterferon alfa-2a
Drug: ribavirin (fixed dose)
Drug: ribavirin (weight-based dose)

First Posted Date: 2009-09-24

Last Posted Date: 2013-10-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 62

Registration Number: NCT00983853

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-770
Drug: VX-809
Drug: VX-809 & VX-770
Drug: Placebo

First Posted Date: 2009-08-27

Last Posted Date: 2010-01-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT00966602

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: VCH-222
Drug: telaprevir

First Posted Date: 2009-08-13

Last Posted Date: 2010-01-07

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 30

Registration Number: NCT00958152

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Phase 2

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Ivacaftor
Drug: Placebo

First Posted Date: 2009-08-06

Last Posted Date: 2015-09-11

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 140

Registration Number: NCT00953706

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Medical Center, Anchorage, Alaska, United States
🇺🇸
Kaiser Permanente Medical Care Program, Oakland, California, United States

and more 31 locations

A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

Not Applicable

Withdrawn

Conditions: Refractory Solid Tumors

First Posted Date: 2009-06-18

Last Posted Date: 2014-01-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Registration Number: NCT00923728

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Completed

Conditions: Hepatitis C

Interventions: Drug: telaprevir

First Posted Date: 2009-06-09

Last Posted Date: 2014-02-27

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 408

Registration Number: NCT00916474

Locations: 🇺🇸
Alabama, Birmingham, Alabama, United States
🇺🇸
California, San Francisco, California, United States
🇺🇸
Colorado, Englewood, Colorado, United States

and more 17 locations

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: VCH-222 or matching placebo
Biological: peginterferon alfa-2a
Drug: ribavirin

First Posted Date: 2009-06-03

Last Posted Date: 2014-03-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 49

Registration Number: NCT00911963

Locations: 🇺🇸
Gastrointestinal Specialists of Georgia PC, Marietta, Georgia, United States
🇺🇸
Henry Ford Health Sytem, Detroit, Michigan, United States
🇺🇸
The liver institute at Methodist hospital, Dallas, Texas, United States

and more 7 locations

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: Ivacaftor

First Posted Date: 2009-05-28

Last Posted Date: 2013-01-18

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 167

Registration Number: NCT00909532

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Kaiser Permanente Medical Care Program, Oakland, California, United States
🇺🇸
Cystic Fibrosis Research Office, Stanford University, Palo Alto, California, United States

and more 62 locations

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Ivacaftor
Drug: Placebo

First Posted Date: 2009-05-28

Last Posted Date: 2012-08-21

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 52

Registration Number: NCT00909727

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Emory Cystic Fibrosis Center, Atlanta, Georgia, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

and more 26 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy